Jacksonville-based Espero Pharmaceuticals, Inc. announced that the U.S. FDA has approved GONITRO™ (nitroglycerin) sublingual powder for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. With this approval, GONITRO™ is the first and only short-acting nitrate in a stabilized crystal granule form available in single dose packets.   The FDA’s approval of GONITRO™ enhances the treatment options available to the more than 8 million U.S. patients suffering with stable angina due to coronary artery disease (CAD), the most common type of heart disease.  Short-acting nitrates are the current standard of care for acute relief of an angina attack. The novel features of a sublingual powder in a portable single dose packet make GONITRO™ attractive to angina patients who need fast relief and want to continue to live an active lifestyle.